VAPO - Earnings announcements

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 Summary Total revenue for the fourth quarter of 2022 was $18.7 million Gross margin was 27.5% in the fourth quarter of 2022 Substantially completed move of manufacturing operations from New Hampshire to Mexico Fiscal Year 2022 Summary Total revenue for 2022 was $66.8 million Launched next generation High Velocity Therapy platform, HVT 2.0 Cost structure has been streamlined which resulted in a decrease in non-GAAP cash operating expenses from $100.8 million in 2021 to $83.6 million in 2022 Worldwide installed base of High Ve

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced preliminary unaudited fourth quarter and full year 2022 net results. Preliminary Fourth Quarter and Full Year 2022 Financial Results For the fourth quarter of 2022, the Company expects net revenue to be in the range of $18.4 million to $18.7 million. For the fourth quarter of 2022, the Company expects gross margin to be in the range of 27% to 28%. For the fourth quarter of 2022, the Com

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2022 financial results. Third Quarter 2022 Summary Total revenue for the third quarter of 2022 was $13.5 million, an increase of 4.4% over the second quarter of 2022 U.S. disposables revenue of $9.5 million reflects a 19.6% increase over U.S. disposables revenue of $7.9 million in the second quarter of 2022 Cost structure has been streamlined which will result in a decrease in Non-GAAP cash operating expenses from $100 million in 2021 to $60 million to $62 million in 2023 Move of manufacturing operations from New Hampshire to Mexico is on track "Our revenue increased sequentially from the s

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789

Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2022 financial results. Second Quarter 2022 Summary Total revenue for the second quarter of 2022 was $13.0 million, a decrease of 37.1% over the second quarter of 2021 Disposables revenue for the second quarter of 2022 was $7.9 million, a decrease of 38.2% over the second quarter of 2021 Worldwide installed base of Precision Flow systems increased by approximately 400 units in the second quarter of 2022 to over 36,100 "The second quarter of 2022 was a tough quarter for us due to low respiratory patient census and Customer destocking of inventory purchased during the Omicron wave in the first

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial (888) 330-2391 for U.S. callers, or +1 (240) 789-2702

Revenue of $21.6 Million In-Line with Preliminary Revenue of $20.5 Million to $21.5 Million Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2022 financial results. First Quarter 2022 Summary Total revenue for the first quarter of 2022 was $21.6 million, a decrease of 33.1% over the first quarter of 2021 Disposables revenue for the first quarter of 2022 was $14.9 million, a decrease of 13.3% over the first quarter of 2021 Worldwide installed base of Precision Flow systems increased by over 500 units in the first quarter of 2022 to over 35,700 "The first quarter of 2022 was challenging as respiratory patient census was low for both seasonal

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Wednesday, May 4, 2022. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial (833) 714-0922 for U.S. callers, or +1 (778) 560-2684 for

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), today announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and reiterated on February 24, 2022) together with its full year 2022 gross margin, operating expense and adjusted EBITDA guidance. Preliminary First Quarter 2022 Financial Results Preliminary revenue for the first quarter of 2022 is expected to be in the range of $20.5 million to $21.5 million, compared to $32.3 million for the first quarter of 2021. Fiscal 2022 Outlook The Company is withdrawing its previously announced annual revenue, gros

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders, today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial (888) 330-2022 for U.S. callers, or +1 (646) 96

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 3, 2021. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial (888) 330-2022 for U.S. callers, or +1 (646) 960-0690

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity. The expansion of disposables production capacity will include the addition of assembly lines in Mexico which will increase capacity by 75% without adding material fixed costs and prepare the Company for the possibility that COVID-19 becomes a permanent part of the respiratory landscape like flu and RSV. This expansion will diversify the Company's manufacturing base and is an element of its gross margin improvement plan. "COVID-19 has accelerated the adoption of our technology, and our installed base has continu

Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Monday, August 9, 2021. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial (833) 714-0922 for U.S. callers, or +1 (778) 560-2684 for

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced an update to its fourth quarter and fiscal year 2020 revenue guidance given on November 4, 2020. Fourth Quarter and Fiscal Year 2020 Outlook For fourth quarter 2020, we now expect revenue in the range of $30.0 million to $33.0 million, which reflects an increase of $12.0 million to $13.0 million over our previously announced revenue guidance of $18.